Lymphoma, Large-Cell Clinical Trial
Official title:
Early Evaluation of the Response of Large B Cell Non Hodgkin’s Lymphoma to Chemotherapy by Positron Emission Tomography Coupled With Computed Tomography (PET/CT)
Patients affected with non-Hodgkin’s large B-cell lymphoma are treated by chemotherapy. The
evaluation of the response to this treatment is made by Positron Emission Tomography
(PET/CT) in many centres where this technology is available. Presently PET scans and CT
scans are being performed before treatment, after 4 cycles of chemotherapy and a few months
after the end of treatment.
The goal of this study is to determine if it is possible to evaluate the efficiency of
chemotherapy treatments after one cycle of treatment instead of waiting after 4 cycles,
using a new scanner that combines PET and CT modalities. Data available from studies on
these combined exams suggest that PET/CT helps to rapidly evaluate the response of the
chemotherapy treatment. We also want to verify if some pathological characteristics measured
from tumor cells will enable doctors to predict in advance the response to treatment.
Participation in this study involves 4 PET/CT exams, which occur before the treatments start, after the first cycle of chemotherapy, after 4 cycles of chemotherapy and then 12 weeks after the end of the treatments. The only additional test performed in this study compared to the regular follow-up of patients that are not in this study is the PET/CT exam after the first cycle. Your participation in this study will not affect treatment since the results of the first PET/CT test will not be communicated. All other tests results will be available in the medical record. ;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00546793 -
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT00298467 -
MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma
|
Phase 2 | |
| Completed |
NCT00051597 -
A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies
|
Phase 1/Phase 2 |